Nada Rayes, Daniel Seehofer, Peter Neuhaus – 30 January 2006

Matthias Günther, Ruth Neuhaus, Tanja Bauer, Wolfgang Jilg, Jan Arne Holtz, Ulrich Bienzle – 30 January 2006 – Patients after orthotopic liver transplantation (OLT) due to hepatitis B virus (HBV)‐related disease are at risk of endogenous hepatitis B reinfection and may receive life long prophylaxis with hepatitis B hyperimmunoglobulin (HBIG). In a previous study 16 of 20 OLT patients were immunized successfully with an adjuvant hepatitis B vaccine.

Nicolas Jabbour, Singh Gagandeep, Yuri Genyk, Rick Selby, Rodrigo Mateo – 30 January 2006

Richard S. Mangus, A. Joseph Tector, Avinash Agarwal, Rodrigo Vianna, Phillip Murdock, Jonathan A. Fridell – 30 January 2006 – Histidine‐tryptophan‐ketoglutarate solution (HTK) and University of Wisconsin solution (UW) have been shown to have similar outcomes in cadaveric kidney, pancreas, and liver transplantation. Our institution changed from UW to HTK as the primary preservation solution for liver, kidney and pancreas transplantation. This study compares the perioperative and first year outcomes of liver transplantation using UW or HTK. Primary use of HTK began on May 1, 2003.

Robert P. Perrillo – 30 January 2006 – The practicing clinician is currently faced with a number of treatment options for chronic hepatitis B. Beginning in 1998 with the licensing of lamivudine and subsequently adefovir, the treatment paradigm shifted from 4 to 6 months of conventional alfa interferon to a year of nucleoside analog therapy. However, prolonged treatment with nucleoside analogs is often needed to optimize virological response.

Hyung Joon Yim, Anna Suk‐Fong Lok – 30 January 2006 – Remarkable progress has been made in our understanding of the natural history of chronic hepatitis B virus (HBV) infection in the past 25 years. Availability of sensitive HBV DNA assays and application of sophisticated immunological techniques led to the recognition that HBV replication persists throughout the course of chronic HBV infection, and host immune response plays a pivotal role in HBV‐related liver disease.

Gianni Biancofiore, Laura Pucci, Elisabetta Cerutti, Giuseppe Penno, Ennia Pardini, Massimo Esposito, Lucia Bindi, Erika Pelati, Anna Romanelli, Stefano Triscornia, Maria P.

Masahide Fukudo, Ikuko Yano, Satohiro Masuda, Toshiya Katsura, Yasuhiro Ogura, Fumitaka Oike, Yasutsugu Takada, Koichi Tanaka, Ken‐ichi Inui – 30 January 2006 – We have compared the pharmacokinetics and pharmacodynamics of cyclosporine between once‐ and twice‐daily dosing regimens in de novo patients of living‐donor liver transplantation (LDLT). A total of 14 patients were enrolled in this study, who had received cyclosporine microemulsion (Neoral) twice a day (BID, n = 5) or once daily in the morning (QD, n = 9) after transplantation.

Ji Hoon Shin, Kyu‐Bo Sung, Hyun‐Ki Yoon, Gi‐Young Ko, Kyoung Won Kim, Sung‐Gyu Lee, Shin Hwang, Chul‐Soo Ahn, Ki‐Hun Kim, Deok‐Bog Moon, Ho‐Young Song, Tae‐Yong Ha – 30 January 2006 – Middle hepatic vein (MHV) reconstruction is performed to drain the right paramedian sector to prevent hepatic venous congestion (HVC). The aim of the present study was to evaluate endovascular stent placement in patients with stenosed and/or occluded interposition vein graft (IVG) to segment V hepatic vein (V5) and segment VIII hepatic vein (V8) after living‐donor liver transplantation (LDLT).

See Ching Chan, Chung Mau Lo, Yik Wong, Chi Leung Liu, Sheung Tat Fan – 30 January 2006 – The right lobe liver graft has become the workhorse of adult‐to‐adult live donor liver transplantation. Donor right hepatectomy is feasible only because of the immense regenerative ability of the liver. The long‐term biological consequences of this very major donor procedure on the donor however are unknown. Twenty‐nine donors of this procedure in our centre, all of whom included the middle hepatic vein, were studied.